tiprankstipranks
Trending News
More News >
SUSMED,Inc. (JP:4263)
:4263
Japanese Market
Advertisement

SUSMED,Inc. (4263) AI Stock Analysis

Compare
0 Followers

Top Page

JP:4263

SUSMED,Inc.

(4263)

Rating:45Neutral
Price Target:
SUSMED, Inc. faces substantial challenges in profitability and cash flow, significantly impacting its financial performance. The technical indicators suggest a mixed market sentiment with a potential for short-term correction. The valuation is unattractive due to ongoing losses and no dividend yield. These factors result in a below-average stock score, highlighting the need for operational improvements and revenue growth to enhance investor appeal.

SUSMED,Inc. (4263) vs. iShares MSCI Japan ETF (EWJ)

SUSMED,Inc. Business Overview & Revenue Model

Company DescriptionSUSMED, Inc. is a healthcare technology company specializing in the development and distribution of digital therapeutic solutions. The company's core focus is on creating applications that integrate medical and scientific expertise to provide therapeutic interventions through digital platforms. These solutions are designed to address various health conditions, offering accessible and efficient healthcare options.
How the Company Makes MoneySUSMED, Inc. generates revenue primarily through the development and commercialization of its digital therapeutic applications. The company partners with healthcare providers, insurance companies, and other stakeholders in the medical field to distribute its products. Revenue streams include licensing fees for the use of its technology, subscription fees from users, and collaborations with pharmaceutical companies for research and development of new therapeutic solutions. Additionally, SUSMED may engage in partnerships to expand its reach and integrate its offerings with existing healthcare systems, thereby enhancing its market presence and revenue potential.

SUSMED,Inc. Financial Statement Overview

Summary
SUSMED, Inc. is facing significant challenges in profitability and cash flow generation. While the company benefits from a strong equity base and no debt, persistent net losses and negative operating cash flow hinder financial stability. The strategic focus should be on improving operational efficiencies and revenue growth to enhance financial performance.
Income Statement
20
Very Negative
The company shows a negative revenue growth trend with decreasing revenue from 2023 to TTM. Gross profit margin remains relatively high, but significant net losses persist, implying poor cost management or excessive expenses. Both EBIT and EBITDA margins are negative, indicating operational inefficiency and a struggle to cover operational costs.
Balance Sheet
70
Positive
The company maintains a robust equity position with a debt-free balance sheet, reflected in a solid equity ratio. However, the substantial losses negatively impact ROE. The high cash reserves provide a buffer against operational losses but do not compensate for the lack of profitability.
Cash Flow
30
Negative
Cash flow from operations remains negative, with no free cash flow growth. The lack of positive operating cash flow relative to net income indicates insufficient cash generation from core operations. The company's reliance on financing activities to sustain cash reserves is a concern.
BreakdownJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue342.58M530.65M316.87M115.49M34.89M
Gross Profit330.85M522.67M306.50M105.73M33.34M
EBITDA-358.99M-43.00M-228.00M-275.60M-96.45M
Net Income-357.42M-50.75M-233.48M-277.55M-96.92M
Balance Sheet
Total Assets4.93B5.10B4.94B1.67B381.56M
Cash, Cash Equivalents and Short-Term Investments4.85B5.05B4.90B1.63B366.13M
Total Debt0.000.000.000.000.00
Total Liabilities327.79M230.33M93.34M97.20M26.36M
Stockholders Equity4.60B4.87B4.85B1.58B355.20M
Cash Flow
Free Cash Flow-240.04M82.40M-177.90M-239.49M-93.19M
Operating Cash Flow-230.76M100.59M-165.28M-235.09M-88.99M
Investing Cash Flow-8.53M-18.19M-20.36M-4.40M-5.83M
Financing Cash Flow37.37M62.36M3.46B1.50B0.00

SUSMED,Inc. Technical Analysis

Technical Analysis Sentiment
Positive
Last Price866.00
Price Trends
50DMA
623.10
Positive
100DMA
593.24
Positive
200DMA
600.07
Positive
Market Momentum
MACD
48.57
Negative
RSI
74.82
Negative
STOCH
90.20
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Positive. The current price of 866 is above the 20-day moving average (MA) of 653.00, above the 50-day MA of 623.10, and above the 200-day MA of 600.07, indicating a bullish trend. The MACD of 48.57 indicates Negative momentum. The RSI at 74.82 is Negative, neither overbought nor oversold. The STOCH value of 90.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:4263.

SUSMED,Inc. Peers Comparison

Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
81
Outperform
¥16.82B9.71
0.59%-12.13%291.07%
75
Outperform
¥5.00B22.56
23.28%
75
Outperform
¥6.65T31.9720.56%0.83%13.56%12.78%
73
Outperform
¥1.08T21.25
1.51%4.13%5.66%
56
Neutral
¥84.52B
2.93%-22.86%-188.19%
52
Neutral
$7.61B0.10-63.03%2.08%16.34%0.32%
45
Neutral
¥14.38B
-79.38%-1239.83%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:4263
SUSMED,Inc.
821.00
270.00
49.00%
JP:3626
TIS Inc.
4,641.00
1,547.11
50.01%
JP:4487
Space Market, Inc.
411.00
95.00
30.06%
JP:4552
JCR Pharmaceuticals Co., Ltd.
685.00
88.01
14.74%
JP:6095
MedPeer, Inc.
762.00
148.72
24.25%
JP:7741
HOYA
19,435.00
1,237.61
6.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: May 03, 2025